KZR 616

Drug Profile

KZR 616

Alternative Names: KZR-616

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Onyx Pharmaceuticals
  • Developer Kezar Life Sciences
  • Class Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 13 Sep 2016 Kezar Life Sciences plans a phase Ib trial for Autoimmune disorders in USA
  • 13 Sep 2016 Kezar Life Sciences plans a phase II trial for Autoimmune disorders in USA
  • 09 Aug 2016 Phase-I clinical trials in Autoimmune disorders in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top